Learning to walk before we run: The mechanics of medical intervention for peripheral arterial disease

Journal of the American College of Cardiology

Volumn 58, Issue 10, 2011, Pages 1077-1079

  Krucoff, Mitchell W ^a   Jones, W Schuyler ^a   Patel, Manesh R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

lipids; magnetic resonance imaging; peripheral vascular disease

Indexed keywords

EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; SIMVASTATIN;

ATHEROMA; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CORONARY ARTERY DISEASE; DRUG MEGADOSE; FUNCTIONAL STATUS; GASTROCNEMIUS MUSCLE; HUMAN; MUSCLE PERFUSION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; WALKING;

EID: 80052105315     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2011.04.035     Document Type: Editorial

References (19)

1. A.T. Hirsch, Z.J. Haskal, and N.R. Hertzer ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) J Am Coll Cardiol 47 2006 e1 e192
2. E.R. Mohler 3rd, W.R. Hiatt, and M.A. Creager Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease Circulation 108 2003 1481 1486 (Pubitemid 37176455)
3. S. Mondillo, P. Ballo, and R. Barbati Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease Am J Med 114 2003 359 364 (Pubitemid 36513683)
4. M.M. McDermott, J.M. Guralnik, and P. Greenland Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease Circulation 107 2003 757 761 (Pubitemid 36222606)
5. A.M. West, J.D. Anderson, and F.H. Epstein Low-density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease J Am Coll Cardiol 58 2011 1068 1076
6. J.D. Anderson, F.H. Epstein, and C.H. Meyer Multifactorial determinants of functional capacity in peripheral arterial disease: uncoupling of calf muscle perfusion and metabolism J Am Coll Cardiol 54 2009 628 635
7. C.M. Kramer Skeletal muscle perfusion in peripheral arterial disease a novel end point for cardiovascular imaging J Am Coll Cardiol Img 1 2008 351 353
8. D.C. Isbell, F.H. Epstein, and X. Zhong Calf muscle perfusion at peak exercise in peripheral arterial disease: measurement by first-pass contrast-enhanced magnetic resonance imaging J Magn Reson Imaging 25 2007 1013 1020 (Pubitemid 46697572)
9. D.C. Isbell, C.H. Meyer, and W.J. Rogers Reproducibility and reliability of atherosclerotic plaque volume measurements in peripheral arterial disease with cardiovascular magnetic resonance J Cardiovasc Magn Reson 9 2007 71 76 (Pubitemid 46018484)
10. D.C. Isbell, S.S. Berr, and A.Y. Toledano Delayed calf muscle phosphocreatine recovery after exercise identifies peripheral arterial disease J Am Coll Cardiol 47 2006 2289 2295 (Pubitemid 43795051)
11. C.M. Gibson, Y.B. Pride, C.P. Hochberg, S. Sloan, M.S. Sabatine, and C.P. Cannon Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22) substudy J Am Coll Cardiol 54 2009 2290 2295
12. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
13. S.E. Nissen, E.M. Tuzcu, and P. Schoenhagen Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial JAMA 291 2004 1071 1080 (Pubitemid 38541684)
14. S.E. Nissen, S.J. Nicholls, and I. Sipahi Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial JAMA 295 2006 1556 1565
15. S.J. Nicholls, E.M. Tuzcu, and I. Sipahi Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis JAMA 297 2007 499 508 (Pubitemid 46220805)
16. V. Pasceri, G. Patti, A. Nusca, C. Pristipino, G. Richichi, and G. Di Sciascio Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) study Circulation 110 2004 674 678 (Pubitemid 39056265)
17. D.E. Cutlip, S. Windecker, and R. Mehran Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351 (Pubitemid 46685903)
18. M.B. Leon, N. Piazza, and E. Nikolsky Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium J Am Coll Cardiol 57 2011 253 269
19. R. Mehran, S.V. Rao, and D.L. Bhatt Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium (BARC) Circulation 123 2011 2736 2747